Trilaciclib dosage in Chinese patients with extensive-stage small cell lung cancer: a pooled pharmacometrics analysis
- 17 May 2024
- journal article
- research article
- Published by Springer Nature in Acta Pharmacologica Sinica
- Vol. 45 (10) , 2212-2225
Abstract
This study aimed to analyze potential ethnic disparities in the dose–exposure–response relationships of trilaciclib, a first-in-class intravenous cyclin-dependent kinase 4/6 inhibitor for treating chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer (ES-SCLC). This investigation focused on characterizing these relationships in both Chinese and non-Chinese patients to further refine the dosing regimen for trilaciclib in Chinese patients with ES-SCLC. Population pharmacokinetic (PopPK) and exposure–response (E–R) analyses were conducted using pooled data from four randomized phase 2/3 trials involving Chinese and non-Chinese patients with ES-SCLC. PopPK analysis revealed that trilaciclib clearance in Chinese patients was approximately 17% higher than that in non-Chinese patients with ES-SCLC. Sex and body surface area influenced trilaciclib pharmacokinetics in both populations but did not exert a significant clinical impact. E–R analysis demonstrated that trilaciclib exposure increased with a dosage escalation from 200 to 280 mg/m2, without notable changes in myeloprotective or antitumor efficacy. However, the incidence of infusion site reactions, headaches, and phlebitis/thrombophlebitis rose with increasing trilaciclib exposure in both Chinese and non-Chinese patients with ES-SCLC. These findings suggest no substantial ethnic disparities in the dose–exposure–response relationship between Chinese and non-Chinese patients. They support the adoption of a 240-mg/m2 intravenous 3-day or 5-day dosing regimen for trilaciclib in Chinese patients with ES-SCLC.Keywords
This publication has 44 references indexed in Scilit:
- Social determinants of health and CDK4/6 inhibitor use and outcomes among patients with metastatic breast cancerBreast Cancer Research and Treatment, 2023
- Racial inequities in second-line treatment and overall survival among patients with metastatic breast cancerBreast Cancer Research and Treatment, 2022
- Racial disparities in neutrophil counts among patients with metastatic breast cancer during treatment with CDK4/6 inhibitorsBreast Cancer Research and Treatment, 2022
- Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy‐induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trialsCancer Medicine, 2021
- Exploratory composite endpoint demonstrates benefit of trilaciclib across multiple clinically meaningful components of myeloprotection in patients with small cell lung cancerInternational Journal of Cancer, 2021
- Evaluation of the Association of Polymorphisms With Palbociclib-Induced Neutropenia: Pharmacogenetic Analysis of PALOMA-2/-3The Oncologist, 2021
- Approaches to handling missing or “problematic” pharmacology data: PharmacokineticsCPT: Pharmacometrics & Systems Pharmacology, 2021
- Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage small cell lung cancerCancer Chemotherapy and Pharmacology, 2021
- Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive‐stage small cell lung cancer: A multicentre, randomised, double‐blind, placebo‐controlled Phase II trialInternational Journal of Cancer, 2020
- Operating characteristics of stepwise covariate selection in pharmacometric modelingJournal of Pharmacokinetics and Pharmacodynamics, 2019